^
    Back
    Association details:
    Biomarker:MET overexpression
    Cancer:Gastric Cancer
    Drug:Orpathys (savolitinib) (c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASCO 2021
    Title:

    Matched therapies for advanced gastric cancer based on genotype: A real-world study in China.

    Published date:
    05/19/2021
    Excerpt:
    ...11 (37%) harbored c-MET amplification/overexpression (received savolitinib or crizotinib, cohort A)....three of 11 patients had an objective response (1 complete response and 2 partial responses, objective response rate (ORR) 27%), disease control rate (DCR) was 45%, median progression-free survival (mPFS) was 2.1 months, and median overall survival (mOS) was 3.7 months.
    DOI:
    10.1200/JCO.2021.39.15_suppl.e16098
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Frontiers
    Title:

    The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer

    Published date:
    09/07/2021
    Excerpt:
    Volitinib demonstrated great antitumor activity in MET and pMET high expression MKN45 cells and xenograft.
    DOI:
    https://doi.org/10.3389/fonc.2021.719217